Exact Mass: 439.2026

2-Tert-Butyl-5-phenyl 4-[(4-piperidin-1-ylphenyl)amino]isothiazol-3(2H)-one 1,1-dioxide

C24H29N3O3S (439.193)

(Tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine

C24H29N3O3S (439.193)

Gymnastatin E

C23H34ClNO5 (439.2125)

latrunculone B

C22H33NO6S (439.2028)

Lagerine

C25H29NO6 (439.1995)

7,8-Dihydro,78-dihydroxy-Gerambullin|gerambullindiol

C22H33NO6S (439.2028)

Dihydroisosakerol

C22H33NO6S (439.2028)

14-Hydroxy-2,3,4,6,7-pentamethoxyphenanthroindolizidine

C25H29NO6 (439.1995)

Phe His His

C21H25N7O4 (439.1968)

His Phe His

C21H25N7O4 (439.1968)

Desmethylmaprotiline glucuronide

C25H29NO6 (439.1995)

His His Phe

C21H25N7O4 (439.1968)

Fmoc-Asp(Ompe)-OH

C25H29NO6 (439.1995)

Fmoc-N-Me-Glu(OtBu)-OH

C25H29NO6 (439.1995)

Fmoc-β-HomoGlu(OtBu)-OH

C25H29NO6 (439.1995)

4-(Diphenylamino)benzaldehyde diphenylhydrazone

C31H25N3 (439.2048)

Fmoc-Aad(otBu)-OH

C25H29NO6 (439.1995)

Vorolanib

C23H26FN5O3 (439.202)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895)[1][2].

N-{2,2-Difluoro-2-[(2R)-piperidin-2-YL]ethyl}-2-[2-(1H-1,2,4-triazol-1-YL)benzyl][1,3]oxazolo[4,5-C]pyridin-4-amine

C22H23F2N7O (439.1932)

Panobinostat Lactate

C24H29N3O5 (439.2107)

C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

2-Tert-Butyl-5-phenyl 4-[(4-piperidin-1-ylphenyl)amino]isothiazol-3(2H)-one 1,1-dioxide

C24H29N3O3S (439.193)

AZ876 is a potent and high-affinity LXR agonist. AZ876 displays 25-fold and 2.5-fold more potent than GW3965 (HY-10627) on human (h)LXRα and hLXRβ respectively[1][2].

Necrox-7

C24H29N3O3S (439.193)

5-methyl-7-(2-methylpropyl)-2-(naphthalen-1-ylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

C26H25N5O2 (439.2008)

2-(1-Adamantyl)-5-(4-ethoxy-3-methoxyphenyl)-5,6-dihydro-[1,2,4]triazolo[5,1-b][1,3]thiazin-7-one

C24H29N3O3S (439.193)

4-[[Oxo-[4-(phenylmethyl)-2,3-dihydro-1,4-benzothiazin-6-yl]methyl]amino]-1-piperidinecarboxylic acid ethyl ester

C24H29N3O3S (439.193)

1-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(5,7-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-methylthiourea

C24H29N3O3S (439.193)

Phe-His-His

C21H25N7O4 (439.1968)

His-His-Phe

C21H25N7O4 (439.1968)

5-(Furan-2-yl)-7-(4-(furan-3-ylmethyl)piperazin-1-yl)-2-(p-tolyl)pyrazolo[1,5-a]pyrimidine

C26H25N5O2 (439.2008)

9-(trifluoromethyl)-2,3,6,7,12,13,16,17-octahydro-1H,5H,11H,15H-pyrido[3,2,1-ij]quinolizino[1,9:6,7,8]chromeno[2,3-f]quinolin-4-ium

C26H26F3N2O+ (439.1997)

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

[(1S)-1-[(2-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

[(1R)-1-[(4-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

N-[(2R,3S,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3R,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3R,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide

C24H29N3O5 (439.2107)

[(8S,9S,10R)-6-ethylsulfonyl-9-[4-[2-(2-pyridinyl)ethynyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C24H29N3O3S (439.193)

[(8R,9S,10S)-6-ethylsulfonyl-9-[4-[2-(2-pyridinyl)ethynyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C24H29N3O3S (439.193)

[(1R)-1-[(2-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

N-[(2S,3R,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3R,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3S,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3S,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3S,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

[(8R,9R,10S)-6-ethylsulfonyl-9-[4-[2-(2-pyridinyl)ethynyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C24H29N3O3S (439.193)

[(8S,9R,10R)-6-ethylsulfonyl-9-[4-[2-(2-pyridinyl)ethynyl]phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C24H29N3O3S (439.193)

3-[4-[(8R,9R,10R)-6-ethylsulfonyl-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile

C24H29N3O3S (439.193)

[(1R)-2-[(3-chlorophenyl)methyl]-7-methoxy-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

His-Phe-His

C21H25N7O4 (439.1968)

LPS 12:1

C18H34NO9P (439.1971)

ST 20:3;O3;Tau

C22H33NO6S (439.2028)

TC-F2

C26H25N5O2 (439.2008)

TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders[1].

(1r,4z,8r,10z,12s,15r,17r)-8,17-dihydroxy-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C22H33NO6S (439.2028)

(20r,21s)-4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaen-21-ol

C25H29NO6 (439.1995)

n-(2-{4-[(6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

(2e,4e,6r)-n-[(1s,2r,4's,5r,5's,6s)-4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl]-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

n-(2-{3-hydroxy-4-[(4-hydroxy-3,7-dimethyloct-6-en-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

8,17-dihydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C22H33NO6S (439.2028)

(2e,4e,6r)-n-[(1r,2s,4's,5s,5's,6r)-4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl]-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

(2e,4e)-n-{4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl}-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

(2e)-n-[2-(4-{[(2e,6s)-6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaen-21-ol

C25H29NO6 (439.1995)

(2e)-n-[2-(3-hydroxy-4-{[(3r,4r)-4-hydroxy-3,7-dimethyloct-6-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)